Adeno-associated viral (AAV) vector based gene therapy for RPE65-associated Leber congenital amaurosis (LCA) and choroideremia (CHM) have entered Phase III and II clinical trials respectively. This evidence concerns the gene RPE65 and Leber congenital amaurosis.